China says it is on track to put boots on Moon by 2030 as Nasa's Artemis struggles with delay
China's plans to put boots on the Moon by 2030 are on track with tests proceeding as per schedule, the country's space agency said, following an early trial of its lunar landing spacecraft last week.
The Asian giant's timeline to land astronauts back on the Moon is still behind the schedule of Nasa's Artemis II crewed mission, which has been delayed until 2027.
Last week, China's space agency announced the successful trial of its prototype Mengzhou next-generation reusable spacecraft and the Lanyue lunar surface lander, adding that their development was 'progressing smoothly', SCMP reported.
In subsequent months, the space agency plans to test the safety and reliability of the country's three-stage superheavy rocket, Long March 10, as well as the Mengzhou spacecraft.
Mengzhou has two modules, one that would return to Earth, and another expendable module to provide propulsion, power and life support for a crew of about six astronauts while they are in space.
'The Long March 10 and Mengzhou spacecraft are carrying out prototype development and testing as planned,' said Lin Xiqiang, deputy director of the China Manned Space Agency (CMSA).
Further ground tests would also assess the spacecraft's emergency escape systems, developed to get the crew to safety in the event of a launch failure.
In earlier reports, the space agency said it expected the spacecraft to attain crewed flight capability around 2027-2028.
'We will strive to ensure the successful completion of all tests to lay a solid foundation for launching humans to the moon as scheduled,' the CMSA deputy director said.
Meanwhile, Nasa's Artemis III crewed mission to the lunar surface has been facing a series of delays.
Both the Chinese and American missions are aiming for a landing near the lunar south pole thought to be rich in water-ice, a resource critical for establishing bases.
Nasa announced in December that its mission to put boots on the Moon would be delayed to mid-2027, after problems were discovered with the heat shield on its Orion spacecraft.
Extensive tests found that material on the spacecraft's heat shield wore away differently than expected.
The heat shield is supposed to provide thermal protection for Orion's crew from the nearly 2,760 degrees Celsius (5,000 degrees Fahrenheit) of temperatures generated when Orion returns through Earth's atmosphere.
The American space agency has been testing changes to Orion's trajectory and enhancements to the heat shield to ensure the spacecraft can keep the crew safe.
'The updates to our mission plans are a positive step toward ensuring we can safely accomplish our objectives at the Moon and develop the technologies and capabilities needed for crewed Mars missions,' said Catherine Koerner, associate administrator for Nasa's Exploration Systems Development Mission Directorate.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
an hour ago
- USA Today
Texas politicians lead effort to study a psychedelic drug. What is ibogaine?
Ibogaine is illegal in the U.S., but growing evidence shows its promise treating the effects of traumatic brain injury and substance use disorder. A once obscure traditional psychedelic plant from Africa has made headlines recently as Texas pushes for more research and a prominent Republican wrote a vigorous endorsement of its possible use for the treatment of addiction and for veterans experiencing mental health issues. Ibogaine is illegal for use in the United States, but a growing body of evidence has shown its promise treating the effects of traumatic brain injury and substance use disorder. Earlier in June, Texas Gov. Greg Abbott signed legislation to allocate $50 million for clinical trials approved by the Food and Drug Administration to study ibogaine. Texas is set to lead research into the drug's benefits treating mental health issues and addiction as a potential medication. Former Energy Secretary Rick Perry, also a former Texas governor, wrote a June 27 Washington Post op-ed supporting ibogaine research and criticizing the legacy of the war on drugs, started by President Richard Nixon and touted by President Ronald Reagan. Perry said he has 'come to realize just how wrong that narrative was.' 'That fear-based messaging kept us from exploring treatments that could have saved countless lives,' Perry wrote. Perry and a growing number of conservatives have argued ibogaine could be one of those treatments. Here's what to know about the drug. What is ibogaine? Ibogaine derives from the root of the iboga plant native to western-central Africa. It's been used in ceremonial rituals for centuries. It has hallucinogenic properties. The United States outlawed ibogaine in 1967 along with other psychotropic drugs. The Controlled Substances Act of 1970 placed it as a schedule I hallucinogenic drug, along with marijuana. Ibogaine's classification prevented researchers from studying its effects. But unlike other schedule 1 drugs such as heroin, ibogaine has anti-addictive properties. There are risks since ibogaine can delay the body's normal electrical signals that control heart rhythm, which could lead to death. Other countries, such as Mexico, have allowed its use. American veterans and others have traveled to smaller, clandestine clinics for treatment to deal with depression, post-traumatic stress disorder and addiction. Many clinics are along the border and around cities such as Tijuana. Why is it in the news? At the state and federal level, there is growing interest in studying psychedelic drugs to treat veterans and others. Texas passed legislation earlier in June to study the drug with a public university alongside a company and hospital, Abbott's office said. Dr. Marty Makary, the FDA commissioner, has said expanding research on psychedelic drugs is a top priority for the Trump administration. In his op-ed, Perry cited the experiences of Morgan and Marcus Luttrell, twin combat veterans, who used ibogaine for recovery. Morgan Luttrell is now a Republican congressman from Texas who has advocated for ibogaine and other psychedelic drugs as treatment options. In January 2025, Perry and W. Bryan Hubbard, an advocate for ibogaine treatment, appeared on Joe Rogan's podcast to discuss ibogaine's benefits as a plant-based medicine. Hubbard led a Kentucky task force that sought to use opioid settlement funds to research ibogaine's effects to treat addiction, but the initiative failed to gain support in the state. Hubbard and Perry eventually launched the Texas Ibogaine Initiative, which helped spur the state funding. What has research shown? Research, such as a Stanford University study of 30 male combat veterans, has shown ibogaine's promise. Coupled with magnesium sulfate to address heart effects, ibogaine appeared to reduce symptoms of PTSD, anxiety and depression, and improve cognitive function from traumatic brain injury, according to the study, published in 2024 in the eminent journal Nature Medicine. Other studies have shown benefits treating addiction and depression. What do critics say? One issue with ibogaine is the ability to produce it, because it is derived from a rare plant and has mostly been used for ceremonial purposes. There is research to help innovate its safe production, but it could be difficult for the drug to be more widely available, as researchers at the University of California, Davis, Institute for Psychedelics and Neurotherapeutics have said. And while it's shown benefits with combat veterans, questions remain on its efficacy among randomized participants. With Texas' research, ibogaine could get closer to FDA approval for its use as a medication.
Newsweek
2 hours ago
- Newsweek
This New Test Could Diagnose Parkinson's With AI
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A new artificial intelligence (AI) tool analyzing short smile videos achieved high accuracy in screening for Parkinson's disease (PD), according to research published by Tariq Adnan, and colleagues in the New England Journal of Medicine (NEJM) Thursday. The model was trained on the largest known video dataset of facial expressions to date, enrolling 1,452 participants, including 391 living with PD. An 87.9 percent overall accuracy in detecting PD using only smile video analysis, the NEJM AI study reported. Researchers reported that the AI model could accurately distinguish between individuals with and without PD based on the analysis of their smiles, even when applied in diverse population samples from North America and Bangladesh. Why It Matters The Parkinson's Foundation says an estimated 90,000 more people will be diagnosed this year, with the number of those suffering expected to be around 1.2 million by 2030. Diagnosing Parkinson's disease early remains a significant challenge because of limited access to clinical expertise and in-person evaluations. AI-driven remote screening tools promise scalable, cost-effective solutions to bridge these healthcare gaps. The findings align with the growing demand for digital healthcare solutions that remove geographical and economic barriers to early neurological disease diagnosis, which is especially relevant to rural and underserved American communities. What To Know The new screening method invited participants to record themselves mimicking facial expressions—including a smile—using an online platform. Research teams then extracted facial landmarks and measured action units to quantify hypomimia, a common motor symptom in PD where facial muscle movement is diminished. Machine learning models were developed using these features, distinguishing people with PD from those without. The approach relied on a broad recruitment strategy, involving participants from North America via social media, email, wellness centers, and research registries, alongside a high-risk cohort from Bangladesh. Trained solely on smile videos, the model achieved a 10-fold cross-validated accuracy of 87.9 percent, a sensitivity of 76.8 percent, and a specificity of 91.4 percent. Validation in external test sets revealed 80.3 percent accuracy in a U.S. clinic dataset and 85.3 percent accuracy in the Bangladesh cohort. While the negative predictive value remained above 92 percent in all settings, the positive predictive value dropped to 35.7 percent among the Bangladeshi participants, reflecting variations in population characteristics. The study found no significant differences in model performance across sex and ethnic subgroups, except for marginally higher accuracy in female participants in Bangladesh. The authors emphasized the generalizability and fairness of the approach, key considerations in the development of clinical AI tools. The video-processing and machine-learning code supporting the study is available to the public on GitHub. However, the study authors noted that raw video data sharing is restricted to comply with U.S. healthcare privacy law (HIPAA), limiting access to de-identified derivative features only. The research received funding from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, among other sources. The work was a collaborative effort involving academic and clinical partners such as the InMotion Parkinson's Disease wellness center and the University of Rochester Center for Health and Technology. The research process also benefited from contributions by staff at Google Research and the University of Rochester, particularly in statistical analysis. Stock image of brain MRI taken November 21, 2018. Stock image of brain MRI taken November 21, 2018. Getty What People Are Saying Tariq Adnan, lead author said in the study conclusion: "Smiling videos can effectively differentiate between individuals with and without PD, offering a potentially easy, accessible, and cost-efficient way to screen for PD, especially when access to clinical diagnosis is limited." What Happens Next? Future steps for the research team involve wider validation of the AI screening method in additional, real-world populations and further refinement of the algorithm to maximize early detection accuracy. Regulatory and clinical translation pathways will determine if and when this technology becomes available in the United States healthcare system.
Yahoo
4 hours ago
- Yahoo
Close-up images of The Red Planet's ridges from Mars Rover show ‘dramatic evidence' of water
Close-up images of a region of Mars scientists had previously only seen from orbit have revealed 'dramatic evidence' of where water once flowed on the Red Planet. The new images taken by NASA's Curiosity Mars rover raises fresh questions about how the Martian surface was changing billions of years ago. Mars once had rivers, lakes, and possibly an ocean, NASA said. Scientists aren't sure why the water eventually dried up, leading the planet to transform into the chilly desert it is today. Curiosity's images show evidence of ancient groundwater crisscrossing low ridges, arranged in what geologists call a boxwork pattern, the space agency said. 'By the time Curiosity's current location formed, the long-lived lakes were gone in Gale Crater, the rover's landing area, but water was still percolating under the surface,' NASA said in a news release. 'The rover found dramatic evidence of that groundwater when it encountered crisscrossing low ridges.' 'The bedrock below these ridges likely formed when groundwater trickling through the rock left behind minerals that accumulated in those cracks and fissures, hardening and becoming cementlike,' the release continued. 'Eons of sandblasting by Martian wind wore away the rock but not the minerals, revealing networks of resistant ridges within.' The rover has been exploring the planet's Mount Sharp since 2014, where the boxwork patterns have been found. Curiosity essentially 'time travels' as it ascends from the oldest to youngest layers, searching for signs of water and environments that could have supported ancient microbial life, NASA explained. 'A big mystery is why the ridges were hardened into these big patterns and why only here,' Curiosity's project scientist, Ashwin Vasavada, said. 'As we drive on, we'll be studying the ridges and mineral cements to make sure our idea of how they formed is on target.' In another clue, scientists observed that the ridges have small fractures filled with the salty mineral calcium sulfate, left behind by groundwater. Curiosity's deputy project scientist, Abigail Fraeman, said it was a 'really surprising' discovery. 'These calcium sulfate veins used to be everywhere, but they more or less disappeared as we climbed higher up Mount Sharp,' Fraeman said. 'The team is excited to figure out why they've returned now.'
